Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1791
- Phase 1/Phase 2478
- Phase 3344
- Phase 4125
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia280
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts102
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT07410403Enrolling by invitation
AI study to predict genetic changes in myeloma cells
This trial uses artificial intelligence to look at individual myeloma cells under a microscope to predict genetic abnormalities (FISH results). It may help doctors understand your myeloma better without waiting for a separate FISH test.
Wuhan, HubeiAges Any age - NCT07410520RecruitingPhase 2
New drug combo for brain lymphoma
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
Nanjing, JiangsuAges 18 years+ - NCT07409454RecruitingPhase 2
Post-transplant treatment for multiple myeloma with a bispecific antibody
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
TianjinAges 18 years+ - NCT07410676RecruitingPhase 1/Phase 2
Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges Any age - NCT07414446Recruiting
Detecting lung blood flow issues with a new ultrasound device
This trial uses a non-invasive ultrasound device to detect abnormal blood flow connections in the lungs, which are common in people with hereditary hemorrhagic telangiectasia (HHT) or a type of stroke called cryptogenic stroke. The goal is to see if the device can find these issues safely and easily without needing an invasive procedure.
Nieuwegein, UtrechtAges 18 years+ - NCT07411079Recruiting
Testing clot-busting drug on brain bleed blood samples
This study collects blood samples from people with and without bleeding risk to test a clot-dissolving drug (tPA) outside the body. It aims to improve minimally invasive surgery for brain hemorrhages.
LilleAges 18–65 - NCT07414511Recruiting
Hemophilia A research study for pregnant families
This study follows pregnant people who carry a severe hemophilia A gene and their babies after birth. It looks at how hemophilia A is passed down and how it affects families, with the goal of improving understanding and care.
Seattle, WashingtonAges Any age - NCT07416045Recruiting
Study on how x-ray radiation affects red blood cells during cancer surgery
This study looks at how radiation from a linear accelerator changes red blood cells in people having surgery for cancer. It may help doctors understand how to better manage blood loss during surgery.
Hangzhou, ZhejiangAges 18–65 - NCT07410247Recruiting
Registry for children with MPN blood cancers
This study tracks children and teens with certain rare blood cancers called myeloproliferative neoplasms (MPNs). By collecting information from many patients, doctors hope to better understand these conditions and improve care for young people.
Erlangen, BavariaAges birth–17 years - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT06822868RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT06821880Recruiting
Tracking infections and quality of life in blood cancer patients
This study uses a smartphone or web app to track infections and quality of life in people with multiple myeloma or chronic lymphocytic leukemia who have a weakened immune system. The goal is to create a better screening tool for infections and understand how the disease and treatment affect daily life.
Innsbruck, TyroliaAges 18 years+ - NCT06823219Recruiting
Long-term endurance training for sickle cell disease
This study tests whether a long-term endurance exercise program can improve physical fitness, reduce complications, and enhance quality of life for people with sickle cell disease. It is designed for patients whose condition is stable but who have had at least one pain crisis in the last three years.
CréteilAges 15 years+ - NCT06823960Recruiting
Zanubrutinib for marginal zone lymphoma in Italy
This study checks how well and how safely zanubrutinib worked for people with marginal zone lymphoma who got the drug through a special access program in Italy. The goal is to learn more about the drug's real-world effects and help future patients.
Alessandria, AlessandriaAges 18 years+ - NCT05066412RecruitingPhase 1
Preventing relapse after a half-matched transplant with modified donor cells
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
Geneva, Canton of GenevaAges 18 years+ - NCT06770010Recruiting
Digital brain training for kids with sickle cell disease
This trial is testing a digital program to help improve working memory (the ability to hold and use information in your mind) for children with sickle cell disease. If you join, you'll use a computer-based training program at home and researchers will see if it works and is easy to use.
Washington D.C., District of ColumbiaAges 7–16 - NCT06826118RecruitingPhase 2
Car t-cell therapy for relapsed follicular lymphoma
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
Xiamen, FujianAges 18 years+ - NCT07399730Recruiting
Study of ravulizumab outcomes in Polish aHUS patients
This study looks at how well patients with aHUS in Poland are doing after treatment with ravulizumab (Ultomiris). It is for people who have already received this drug through the national program and agree to share their health information.
GdanskAges 18 years+ - NCT07404644Recruiting
Study of vonicog alfa in children with von Willebrand disease
This study looks at how well vonicog alfa (a lab-made version of a missing blood protein) works to control bleeding in children under 18 with von Willebrand disease. It follows children who are already prescribed this treatment in Japan to see how safe and effective it is in real life.
Tokyo, TokyoAges Up to 17 years - NCT07401823Enrolling by invitationPhase 2
Long-term follow-up study for sickle cell disease treatment
This study is a follow-up for people with sickle cell disease who already saw a benefit in fetal hemoglobin from the earlier Pioneer study. It tests the long-term safety and effects of the study drug pociredir (also called FTX-6058) while allowing most standard sickle cell treatments except hydroxyurea.
Little Rock, ArkansasAges 18 years+ - NCT07400029RecruitingPhase 2
Obecabtagene autoleucel for B-cell ALL in remission
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
Duarte, CaliforniaAges 40 years+ - NCT07405424Recruiting
Spiritual care support for adults with new acute leukemia
This study tests whether adding spiritual care to standard treatment helps adults newly diagnosed with acute leukemia feel better emotionally and spiritually. You may join if you are starting your first hospital treatment for AML or ALL.
Chicago, IllinoisAges 18 years+ - NCT07398963RecruitingPhase 1
Virus-based CAR-T therapy for relapsed B-cell lymphoma
This trial uses a modified virus to deliver CAR-T cells directly into tumors, aiming to treat B-cell lymphoma that has come back or not responded to other treatments. It may be an option if your lymphoma is CD19-positive and you've tried at least two prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT07406139RecruitingPhase 4
PCC treatment for hemophilia A with inhibitors
This trial tests a clotting factor product called PCC (prothrombin complex concentrate) to treat bleeding episodes in people with hemophilia A who have developed inhibitors. It's for those who are 12–65 and have frequent joint bleeds.
Tianjin, Tianjin MunicipalityAges 12–65
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,288 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.